Skip to main content
SpringerLink
Log in

Diagnostic usefulness of FDG PET for pancreatic mass lesions

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

The purpose of this study was to investigate the feasibility of [18F]2-deoxy-2-fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with a pancreatic mass by comparing the results with those of X-ray computed tomography (CT) and magnetic resonance (MR) imaging.Methods: Eighty-six patients with pancreatic lesions, included 65 malignant tumors and 21 benign masses (55 masses were proven histologically and the others were diagnosed clinically), were studied. The diagnostic factors of CT and MR imaging were evaluated, and those of FDG PET were also evaluated for malignant and benign masses by visual interpretation and quantitative interpretation with the standardized uptake value (SUV) and SUV gluc which was designed to reduce the effects of a high blood sugar level. Visual interpretations were evaluated only in FDG PET images, and quantitative interpretations were evaluated by referring to CT and/or MR imaging. The correlation between SUV and the degree of histological differentiation in pancreatic ductal adenocarcinoma was investigated.Results: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for CT imaging were 91, 62, 88, 68 and 84%, and for MR imaging 78, 70, 88, 54 and 76%, respectively. In visual interpretation of FDG PET images, the sensitivity, specificity, PPV, NPV and accuracy were 82, 81, 93, 59 and 81%, respectively. Significant differences between malignant and benign lesions existed in SUV and SUV gluc (p<0.0001, each). With the cutoff value of SUV as 2.1 and SUV gluc as 2.2, the accuracy of diagnosis was maximal. With that cutoff value, the sensitivity, specificity, PPV, NPV and accuracy for SUV were 89, 76, 92, 70 and 86%, and for SUV gluc 91, 76, 92, 73 and 87%, respectively. The sensitivity and NPV of SUV gluc were higher than those of SUV, which suggests that SUV gluc may be more useful in reducing the number of overlooked malignant tumors. The specificity and PPV of FDG PET were superior to those of CT and MR imaging. There were no significant differences between the SUVs of moderately differentiated adenocarcinomas and those of well differentiated adenocarcinomas.Conclusion: To improve the diagnostic procedure for classifying masses, FDG PET with not only SUV but also SUV corrected by the blood sugar level is required in addition to morphological diagnosis by CT and/or MR imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Tamakoshi A, Lin Y, Ohno Y. Mortality and incidence of pancreatic cancer.Sogorinsho 1999; 48: 1640–1648. (in Japanese)

    Google Scholar 

  2. Bida GT, Satyamurthy N, Barrio JR. The synthesis of 2-[F-18] fluoro-2-deoxy-d-glucose using glycals: a reexamination.J Nucl Med 1984; 25: 1327–1334.

    CAS  PubMed  Google Scholar 

  3. Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool.Invest Radiol 1986; 22: 360–371.

    Article  Google Scholar 

  4. Strauss LG, Conti PS. The applications of PET in clinical oncology.J Nucl Med 1991; 32: 623–648; discussion 649–650.

    CAS  PubMed  Google Scholar 

  5. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.Eur J Nucl Med 1997; 24: 678–682.

    CAS  PubMed  Google Scholar 

  6. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.J Nucl Med 1998; 39: 1030–1033.

    CAS  PubMed  Google Scholar 

  7. Freeny PC, Traverso LW, Ryan JA. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography.Am J Surg 1993; 165: 600–606.

    Article  CAS  PubMed  Google Scholar 

  8. Semelka RC, Ascher SM. MR imaging of the pancreas.Radiology 1993; 188: 593–602.

    CAS  PubMed  Google Scholar 

  9. Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.Eur J Nucl Med 1995; 22: 32–39.

    Article  CAS  PubMed  Google Scholar 

  10. Procacci C, Biasiutti C, Carbognin G, Accordini S, Bicego E, Guarise A, et al. Characterization of cystic tumors of the pancreas: CT accuracy.J Comput Assist Tomogr 1999; 23: 906–912.

    Article  CAS  PubMed  Google Scholar 

  11. Müller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging.Radiology 1994; 190: 745–751.

    PubMed  Google Scholar 

  12. Vellet AD, Romano W, Bach DB, Passi RB, Taves DH, Munk PL. Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT and MR imaging at 1.5 T.Radiology 1992; 183: 87–95.

    CAS  PubMed  Google Scholar 

  13. Klever P, Bares R, Fass J, Büll U, Schumpelick V. PET with fluorine-18 deoxyglucose for pancreatic disease [letter].Lancet 1992; 340: 1158–1159.

    Article  CAS  PubMed  Google Scholar 

  14. Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, et al. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer.J Nucl Med 1995; 36: 229–235.

    CAS  PubMed  Google Scholar 

  15. Syrota A, Comar D, Cerf M, Plummer D, Mazière M, Kellershohn C. [11C]methionine pancreatic scanning with positron emission computed tomography.J Nucl Med 1979; 20: 778–781.

    CAS  PubMed  Google Scholar 

  16. Kirchner PT, Ryan J, Zalutsky M, Harper PV. Positron emission tomography for the evaluation of pancreatic disease.Semin Nucl Med 1980; 10: 374–391.

    Article  CAS  PubMed  Google Scholar 

  17. Stollfuss JC, Glatting G, Friess H, Kocher F, Beger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-d-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.Radiology 1995; 195: 339–344.

    CAS  PubMed  Google Scholar 

  18. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al. F-18 fluorodeoxyglucose PETin vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.Radiology 1994; 192: 79–86.

    CAS  PubMed  Google Scholar 

  19. Friess H, Langhans J, Ebert M, Beger HG, Stollfuss J, Reske SN, et al. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-d-glucose positron emission tomography.Gut 1995; 36: 771–777.

    Article  CAS  PubMed  Google Scholar 

  20. Langen KJ, Braun U, Rota Kops E, Herzog H, Kuwert T, Nebeling B, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas.J Nucl Med 1993; 34: 355–359.

    CAS  PubMed  Google Scholar 

  21. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA. FDG-PET evaluation of indeterminate pancreatic masses.J Comput Assist Tomogr 1996; 20: 363–369.

    Article  CAS  PubMed  Google Scholar 

  22. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with18F-FDG to detect residual disease after therapy for malignant lymphoma.Nucl Med Commun 1998; 19: 1055–1063.

    Article  CAS  PubMed  Google Scholar 

  23. Reisser C, Haberkorn U, Strauss LG. The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors.J Otolaryngol 1993; 22: 231–238.

    CAS  PubMed  Google Scholar 

  24. Imdahl A, Nitzsche E, Krautmann F, Hogerle S, Boos S, Einert A, et al. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.Br J Surg 1999; 86: 194–199.

    Article  CAS  PubMed  Google Scholar 

  25. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.J Nucl Med 1998; 39: 1727–1735.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Osaka City University School of Medicine, 1-4-3, Asahi-machi, Abenoku, 545-8585, Osaka, Japan

    Joji Kawabe & Hironobu Ochi

  2. Department of Surgical Oncology, Osaka City University School of Medicine, 1-4-3, Asahi-machi, Abenoku, 545-8585, Osaka, Japan

    Bunzo Nakata & Kosei Hirakawa-Y. S. Chung

  3. Department of Radiology, Osaka City University School of Medicine, 1-4-3, Asahi-machi, Abenoku, 545-8585, Osaka, Japan

    Koichi Koyama, Terue Okamura & Ryusaku Yamada

Authors
  1. Koichi Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terue Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joji Kawabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bunzo Nakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kosei Hirakawa-Y. S. Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hironobu Ochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ryusaku Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Koichi Koyama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koyama, K., Okamura, T., Kawabe, J. et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 15, 217–224 (2001). https://doi.org/10.1007/BF02987835

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02987835

Key words

Search

Navigation